{"id":"https://openalex.org/W4399346145","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1103","title":"Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.","display_name":"Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.","publication_year":2024,"publication_date":"2024-06-01","ids":{"openalex":"https://openalex.org/W4399346145","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1103"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.1103","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1103","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1103","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1103","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1103","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039802529","display_name":"Neelima Vidula","orcid":"https://orcid.org/0000-0002-5963-7052","observed_orcids":["https://orcid.org/0000-0002-5963-7052"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neelima Vidula","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023123154","display_name":"Jennifer A. Hutchinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Hutchinson","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Abigail McLaren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abigail McLaren","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043140897","display_name":"Lianne Y. Ryan","orcid":"https://orcid.org/0009-0009-1898-550X","observed_orcids":["https://orcid.org/0009-0009-1898-550X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lianne Ryan","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028403057","display_name":"Andrzej Niemierko","orcid":"https://orcid.org/0000-0002-8895-5500","observed_orcids":["https://orcid.org/0000-0002-8895-5500"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrzej Niemierko","raw_affiliation_strings":["Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034972183","display_name":"Aditya Bardia","orcid":"https://orcid.org/0000-0003-4885-1157","observed_orcids":["https://orcid.org/0000-0003-4885-1157"]},"institutions":[{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aditya Bardia","raw_affiliation_strings":["UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA","institution_ids":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"16_suppl","first_page":"1103","last_page":"1103"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9570000171661377},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.6819999814033508},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.9779999852180481},{"id":"https://openalex.org/keywords/immunotherapy-toxicity","display_name":"immunotherapy toxicity","score":0.8429999947547913},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":1.0},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8840000033378601},{"id":"https://openalex.org/keywords/immune-related-hypothyroidism","display_name":"immune-related hypothyroidism","score":0.9520000219345093},{"id":"https://openalex.org/keywords/immune-related-nephritis","display_name":"immune-related nephritis","score":0.8560000061988831},{"id":"https://openalex.org/keywords/immune-related-dermatitis","display_name":"immune-related dermatitis","score":0.578000009059906},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.671999990940094},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.6970000267028809},{"id":"https://openalex.org/keywords/immune-related-endocrinopathy","display_name":"immune-related endocrinopathy","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9302828907966614},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6978580951690674},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6715856194496155},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6628535985946655},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6391414999961853},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5574891567230225},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5319633483886719},{"id":"https://openalex.org/C2779075594","wikidata":"https://www.wikidata.org/wiki/Q8084905","display_name":"Autoimmune disease","level":3,"score":0.5214526057243347},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.46142297983169556},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.44043660163879395},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3961261212825775},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3582706153392792}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2024.42.16_suppl.1103","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1103","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1103","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1103","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1200/jco.2024.42.16_suppl.1103","doi":"https://doi.org/10.1200/jco.2024.42.16_suppl.1103","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1200/jco.2024.42.16_suppl.1103","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2024.42.16_suppl.1103","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4399346145.pdf","grobid_xml":"https://content.openalex.org/works/W4399346145.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4396596919","https://openalex.org/W7125539253","https://openalex.org/W7161989781","https://openalex.org/W4399324203","https://openalex.org/W7162652216","https://openalex.org/W3005456302","https://openalex.org/W4411289187","https://openalex.org/W7118195542","https://openalex.org/W4409328706","https://openalex.org/W4411289999"],"abstract_inverted_index":{"1103":[0],"Background:":[1],"Pembrolizumab":[2],"is":[3,48],"approved":[4,17],"for":[5,18,140,204,390],"early":[6,85],"and":[7,14,25,60,67,80,86,90,118,132,151,169,206,272,307,330,380],"advanced":[8,19],"triple":[9],"negative":[10],"breast":[11,34,65,88,149,173],"cancer":[12,35,66,150,174],"(TNBC),":[13],"atezolizumab":[15],"was":[16,112,185,202,211,233,247,301,324,367],"TNBC.":[20],"Toxicity":[21],"of":[22,159,223,231,295,309,315,322,332,335,365,382,393],"immunotherapy":[23,54],"(IO)":[24],"immune":[26,244,377],"related":[27,245,257,378],"adverse":[28],"events":[29],"(irAEs)":[30],"in":[31,53,62,82,191,195,208,235,249,284,303,326,369,395],"patients":[32,63,83,147,171,370],"with":[33,36,64,84,126,138,148,172,299,371],"an":[37,50,106],"underlying":[38,91,372,384],"autoimmune":[39,46,68,92,97,153,177,373,385],"disease":[40,47,69,93,98,154,178],"are":[41],"not":[42,290],"well":[43],"understood":[44],"as":[45],"often":[49],"exclusion":[51],"criterion":[52],"trials.":[55],"Understanding":[56],"real-world":[57],"IO":[58,78,100,104,116,160,183,210,224,300,317,351],"toxicity":[59,79,117],"irAEs":[61,81,119,232,323,336,346,366,394],"may":[70],"inform":[71],"clinical":[72],"decision":[73],"making.":[74],"Methods:":[75],"We":[76],"studied":[77],"metastatic":[87],"cancer,":[89],"vs.":[94,193,218,238,252,261,268,276,328],"those":[95],"without":[96,176],"(at":[99],"start)":[101],"who":[102],"received":[103],"at":[105,182],"academic":[107],"institution.":[108],"A":[109,226,361],"retrospective":[110],"review":[111],"conducted":[113],"to":[114,157],"identify":[115],"(CTCAE":[120],"v":[121],"5.0).":[122],"Cohorts":[123,144],"were":[124,337,353],"compared":[125],"Pearson\u2019s":[127],"chi-squared":[128],"test":[129,135],"(categorical":[130],"variables)":[131],"Wilcoxon":[133],"rank-sum":[134],"(continuous":[136],"variables),":[137],"p<0.05":[139],"statistical":[141,292],"significance.":[142,293],"Results:":[143],"had":[145,280],"23":[146],"\u22651":[152],"(AD)":[155],"prior":[156],"receipt":[158],"(thyroid:":[161],"48%,":[162],"rheumatologic:":[163],"26%,":[164],"gastrointestinal:":[165],"13%,":[166],"dermatologic:":[167],"9%),":[168],"106":[170],"but":[175,286],"(non-AD).":[179],"Median":[180],"age":[181],"start":[184],"63":[186],"(interquartile":[187],"range":[188],"[IQR]":[189],"54-69)":[190],"AD":[192,205,236,250,298,327],"50":[194],"non-AD":[196,239,253,269],"(IQR":[197],"39-59).":[198],"Stage":[199],"I-III/IV":[200],"distribution":[201],"39%/61%":[203],"67%/33%":[207],"non-AD.":[209],"mainly":[212],"pembrolizumab":[213],"(AD:":[214,259,266,274,339,355],"87%;":[215],"non-AD:":[216,262,277,341,357],"85%)":[217],"atezolizumab.":[219],"Table":[220],"depicts":[221],"characteristics":[222],"toxicity.":[225],"significantly":[227],"higher":[228,282,362],"overall":[229,363],"rate":[230,364],"seen":[234],"(96%)":[237],"(59%)":[240],"[p<0.001].":[241],"Significantly":[242],"greater":[243,376],"transaminitis":[246,379],"observed":[248,302,368],"(52%)":[251],"(24%)":[254],"[p=0.006].":[255],"Immune":[256],"hypothyroidism":[258],"30%":[260],"15%,":[263],"p=0.08),":[264,271],"nephritis":[265],"9%":[267,275],"2%,":[270],"hyperthyroidism":[273],"3%,":[278],"p=0.19)":[279],"numerically":[281],"rates":[283,331],"AD,":[285],"these":[287],"findings":[288],"did":[289],"achieve":[291],"Flare":[294],"the":[296,383,388],"baseline":[297],"6/23":[304],"(26%)":[305],"patients,":[306],"50%":[308],"flares":[310],"occurred":[311],"within":[312],"1":[313],"month":[314],"starting":[316],"(range":[318],"1-5":[319],"months).":[320],"Management":[321],"similar":[325,338],"non-AD,":[329],"full":[333],"resolution":[334],"55%;":[340],"61%,":[342],"p=0.65).":[343],"Late":[344],"onset":[345],"(>":[347],"3":[348],"months":[349],"after":[350],"discontinuation)":[352],"rare":[354],"12%;":[356],"4%,":[358],"p=0.21).":[359],"Conclusions:":[360],"disease,":[374,386],"including":[375],"flare":[381],"suggesting":[387],"need":[389],"close":[391],"monitoring":[392],"this":[396],"population.":[397],"[Table:":[398],"see":[399],"text]":[400]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2024-06-05T00:00:00"}